Compared with the control and iEV-NC groups, melanoma-bearing mice treated with iEV-150 showed enhanced antitumor responses when receiving the same dose of anti-PD-1 or anti-LAG3 antibodies, as reflected by reduced tumor size and weight (Figure 8H-J). Here, LAG3 is linked to neoplasm.